Janux Therapeutics
JANX
190 hedge funds and large institutions have $828M invested in Janux Therapeutics in 2026 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 66 increasing their positions, 54 reducing their positions, and 28 closing their positions.
64% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 28
22% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 54
8% more funds holding
Funds holding: 176 → 190 (+14)
8% more call options, than puts
Call options by funds: $7.2M | Put options by funds: $6.69M
4% less capital invested
Capital invested by funds: $860M → $828M (-$32.1M)
5.47% less ownership
Funds ownership: 103.42% → 97.95% (-5.5%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$18.6M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$15.9M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$15.1M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$11.1M |
| 5 |
ICM
Irenic Capital Management
New York
|
+$10.5M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$19.1M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$15.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.4M |
| 4 |
O
OrbiMed
New York
|
-$13.3M |
| 5 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
-$10.6M |
JANX Hedge Fund Activity: Q1 2026 in Review
190 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q1 2026, worth a combined $828M — down 3.7% from $860M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new JANX positions and 28 closed out — a net gain of 18 holders — while 66 added to existing stakes and 54 trimmed.
The largest buyer was BlackRock, adding an estimated $18.6M. The largest seller was State Street, cutting an estimated $19.1M.
- 190 institutional investors held Janux Therapeutics (JANX) as of Q1 2026, up from 176 in Q4 2025.
- Funds reported $828M of Janux Therapeutics stock for Q1 2026, down 3.7% quarter-over-quarter.
- 46 funds opened new Janux Therapeutics positions in Q1 2026 and 28 closed out, a net change of +18 holders.
- The largest Janux Therapeutics buyer in Q1 2026 was BlackRock, an estimated $18.6M added.
- The largest Janux Therapeutics seller in Q1 2026 was State Street, an estimated $19.1M sold.
Based on aggregated 13F filings for Q1 2026.